SARS News and Research

RSS

A novel approach to improve the stability of Remdesivir

A recent study discusses a novel method to enhance the stability of Remdesivir.

28 Oct 2021

A new approach to selectively turn on gene therapies in target cells

Researchers at MIT and Harvard University have designed a way to selectively turn on gene therapies in target cells, including human cells.

28 Oct 2021

Third dose of Covid-19 vaccine benefits dialysis patients

In some patients, the immune system responds poorly to the second vaccination dose. This changes with the third shot.

28 Oct 2021

Study suggests third dose of the Pfizer vaccine could reduce SARS-CoV-2 transmission

A new study examined protection against symptomatic coronavirus disease 2019 (COVID-19) from non-Delta variants using data from randomized control trials.

28 Oct 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Researchers investigated the neutralizing antibody response that different mRNA vaccines induce in both previously convalescent and SARS-CoV-2 naïve individuals.

28 Oct 2021

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

In this study, a team of researchers from Japanese institutions provide a panel of broadly neutralizing nanobodies that detect four VOCs.

28 Oct 2021

Two-dose SARS-CoV-2 vaccine effectiveness against infection and hospitalization in Canada

Authors from varying Canadian institutes report on two-dose vaccine effectiveness against infection and hospitalization.

28 Oct 2021

Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows

The results of a new randomized clinical trial, published in The Lancet Global Health, have demonstrated that using fluvoxamine to treat high-risk outpatients with early-diagnosed COVID-19 reduced the need for prolonged observation in an emergency setting or hospitalization, compared to a control group who received a placebo.

28 Oct 2021

Japanese study on SARS-CoV-2 breakthrough infections

Researchers evaluated SARS-CoV-2 incidence in Japan regarding the timing of the vaccination program and surge in COVID-19 cases among the staff of a large referral hospital in Tokyo. This study is posted to the medRxiv* preprint server.

28 Oct 2021

N antibodies following SARS-CoV-2 Alpha and Delta infections by vaccination status

A new study, published on the medRxiv* preprint server, has focused on the use of anti-nucleocapsid (N) antibody positivity as a marker of SARS-CoV-2 infection. In the present study, these antibody markers were evaluated using serological surveillance studies post-vaccination amidst circulation of variants of concern.

28 Oct 2021

Routine surveillance helps detect asymptomatic SARS-CoV-2 vaccine breakthrough infections

In a study published in Annals of Internal Medicine, researchers from Italy systematically monitored 2,397 HCWs who were fully vaccinated with BNT162 at the ASST Settelaghi hospitals in Lombardy, Italy during February 2021. HCWs who worked in 8 wards deemed at “high risk” for infection from attending patients had to undergo mandatory nasopharyngeal swab testing with SARS-CoV-2 polymerase chain reaction every two weeks. HCWs working in 8 “moderate-risk” wards were tested every four weeks.

28 Oct 2021

COVID vaccines deployed in US highly effective at reducing hospitalizations and deaths

Researchers in the United States have conducted a large-scale study showing that the two-dose regimen vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) appear to be highly effective and durable in reducing the risk of hospitalizations and deaths following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Oct 2021

SARS-CoV-2 vaccination lowers risk of several outcomes after breakthrough infection

Researchers at the University of Oxford have conducted a study showing that vaccination against coronavirus disease 2019 (COVID-19) is associated with a lower risk of several sequelae among those who experience breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Oct 2021

SARS News and Research

A novel approach to improve the stability of Remdesivir

A new approach to selectively turn on gene therapies in target cells

Third dose of Covid-19 vaccine benefits dialysis patients

Study suggests third dose of the Pfizer vaccine could reduce SARS-CoV-2 transmission

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

Two-dose SARS-CoV-2 vaccine effectiveness against infection and hospitalization in Canada

Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows

Japanese study on SARS-CoV-2 breakthrough infections

N antibodies following SARS-CoV-2 Alpha and Delta infections by vaccination status

Routine surveillance helps detect asymptomatic SARS-CoV-2 vaccine breakthrough infections

COVID vaccines deployed in US highly effective at reducing hospitalizations and deaths

SARS-CoV-2 vaccination lowers risk of several outcomes after breakthrough infection

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

Undetected SARS-CoV-2 community transmission drove the first wave of COVID-19

COVID-19 and subacute neuropsychiatric symptoms in adolescents

The difference in the dynamics of SARS-COV-2 variants

Taking lessons in molecular therapeutics from earthworms to combat COVID

How do COVID-19 vaccination mandates affect vaccine uptake?

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News